Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when ...
The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they ...
Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...
Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...
The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results